

REGENERON

Regeneron Announces Upcoming Investor Conference Presentations

March 3, 2020

TARRYTOWN, N.Y., March 3, 2020 /PRNewswire/ -- Regeneron Pharmaceuticals, Inc. (NASDAQ: **REGN**) will webcast management participation as follows:

- J.P. Morgan 2020 Biotech Conference Call Series at 12:00 p.m. ET on Friday, March 6, 2020
- Oppenheimer 30th Annual Healthcare Conference at 8:35 a.m. ET on Wednesday, March 18, 2020

The sessions may be accessed from the "Investors & Media" page of Regeneron's website at <http://investor.regeneron.com/events-and-presentations>. Replays of the webcasts will be archived on the Company's website for at least 30 days.

About Regeneron Pharmaceuticals, Inc.

Regeneron is a leading biotechnology company that invents life-transforming medicines for people with serious diseases. Founded and led for over 30 years by physician-scientists, our unique ability to repeatedly and consistently translate science into medicine has led to seven FDA-approved treatments and numerous product candidates in development, all of which were homegrown in our laboratories. Our medicines and pipeline are designed to help patients with eye diseases, allergic and inflammatory diseases, cancer, cardiovascular and metabolic diseases, infectious diseases, pain and rare diseases.

Regeneron is accelerating and improving the traditional drug development process through its proprietary *VelociSuite*[®] technologies, such as *VelocImmune*[®] which produces optimized fully-human antibodies, and ambitious research initiatives such as the Regeneron Genetics Center, which is conducting one of the largest genetics sequencing efforts in the world.

For additional information about the company, please visit www.regeneron.com or follow @Regeneron on Twitter.

Contact Information:

Investor Relations

Justin Holko

914.847.7786

justin.holko@regeneron.com

Corporate Communications

Hala Mirza

914.847.3422

hala.mirza@regeneron.com

 View original content: <http://www.prnewswire.com/news-releases/regeneron-announces-upcoming-investor-conference-presentations-301015780.html>

SOURCE Regeneron Pharmaceuticals